Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial (Q38905814)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial (English)

1 reference

Europe PubMed Central

7 September 2017

0 references

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Amanda Mocroft

1 reference

Europe PubMed Central

7 September 2017

Christine Katlama

8

object named as

Christine Katlama

1 reference

Europe PubMed Central

7 September 2017

Stéphane De Wit

9

object named as

Stephane De Wit

1 reference

Europe PubMed Central

7 September 2017

Antonella Castagna

object named as

Antonella Castagna

13

0 references

Geneviève Chêne

15

object named as

Genevieve Chene

1 reference

Europe PubMed Central

7 September 2017

7

object named as

Peter Reiss

1 reference

Europe PubMed Central

7 September 2017

5

object named as

Jan Gerstoft

1 reference

Europe PubMed Central

7 September 2017

4

object named as

Cedrick Wallet

1 reference

Europe PubMed Central

7 September 2017

10

object named as

Laura Richert

1 reference

Europe PubMed Central

7 September 2017

Babiker M A Abdel-Banat

11

object named as

Abdel Babiker

1 reference

Europe PubMed Central

7 September 2017

François Raffi

16

object named as

Francois Raffi

1 reference

Europe PubMed Central

7 September 2017

Pierre-Marie Girard

14

object named as

Pierre-Marie Girard

1 reference

Europe PubMed Central

7 September 2017

author name string

Jose I Bernardino

1

1 reference

Europe PubMed Central

7 September 2017

Patrick W Mallon

3

1 reference

Europe PubMed Central

7 September 2017

Charlotte Russell

6

1 reference

Europe PubMed Central

7 September 2017

Antonio Buño

12

1 reference

Europe PubMed Central

7 September 2017

Jose R Arribas

17

1 reference

Europe PubMed Central

7 September 2017

NEAT001/ANRS143 Study Group

18

1 reference

Europe PubMed Central

7 September 2017

publication date

30 September 2015

1 reference

Europe PubMed Central

7 September 2017

The lancet. HIV

1 reference

Europe PubMed Central

7 September 2017

2

1 reference

Europe PubMed Central

7 September 2017

11

1 reference

Europe PubMed Central

7 September 2017

e464-73

1 reference

Europe PubMed Central

7 September 2017

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative contribution of HIV infection, demographics and body mass index to bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Stable bone density in HAART-treated individuals with HIV: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fractures after antiretroviral initiation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Aging with HIV: osteoporosis and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS).

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900181-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3018(15)00181-2

1 reference

Europe PubMed Central

7 September 2017

release_3bfikojwwndcrbyzbx7t6zkfwi

1 reference

https://api.fatcat.wiki/v0/release/3bfikojwwndcrbyzbx7t6zkfwi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38905814&oldid=1985472000"